Biomarin Operating Income from 2010 to 2025

BMRN Stock

USD 71.53 0.46 0.64%

Biomarin Pharmaceutical Operating Income yearly trend continues to be very stable with very little volatility. Operating Income is likely to grow to about 508.4 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Biomarin Pharmaceutical generates from its operations. View All Fundamentals

Operating Income

First Reported

1999-03-31

Previous Quarter

113.9 M

Current Value

161.4 M

Quarterly Volatility

69 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.2 M, Interest Expense of 17.9 M or Selling General Administrative of 558.9 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.91. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Operating Income Growth Pattern

Below is the plot of the Operating Income of Biomarin Pharmaceutical over the last few years. Operating Income is the amount of profit realized from Biomarin Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Biomarin Pharmaceutical is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Biomarin Pharmaceutical's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Biomarin Operating Income Regression Statistics

	Arithmetic Mean	(30,960,144)
	Geometric Mean	105,202,916
	Coefficient Of Variation	(938.73)
	Mean Deviation	175,348,320
	Median	(60,013,000)
	Standard Deviation	290,632,048
	Sample Variance	84467T
	Range	1.3B
	R-Value	0.53
	Mean Square Error	64950.9T
	R-Squared	0.28
	Significance	0.03
	Slope	32,435,093
	Total Sum of Squares	1267004.8T

Biomarin Operating Income History

	2025	508.4 M
	2024	484.2 M
	2023	194.4 M
	2022	57.5 M
	2021	-60 M
	2020	-96.3 M
	2019	-125.5 M

Other Fundumenentals of Biomarin Pharmaceutical

Non Operating Income Net Other

Biomarin Pharmaceutical Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.03	-0.11	0.4	0.95	0.78	0.97	0.41	0.46	-0.14	0.77	0.64	0.98	0.42	0.79	0.97	0.84	0.9	0.73	-0.48	0.8	0.67	0.74
Total Stockholder Equity	0.99		-0.09	0.01	0.31	0.97	0.68	0.97	0.31	0.37	-0.22	0.69	0.56	0.97	0.37	0.73	0.99	0.82	0.85	0.7	-0.46	0.85	0.73	0.82
Net Debt	0.03	-0.09		-0.64	0.38	-0.16	0.54	-0.09	0.55	0.65	0.04	0.34	0.42	0.04	0.0	0.39	-0.12	0.06	0.26	0.19	-0.16	-0.21	-0.37	-0.47
Retained Earnings	-0.11	0.01	-0.64		-0.84	0.09	-0.57	-0.06	-0.76	-0.65	-0.35	-0.55	-0.44	-0.22	-0.39	-0.5	0.1	-0.03	-0.39	-0.26	0.53	0.44	0.47	0.45
Accounts Payable	0.4	0.31	0.38	-0.84		0.26	0.66	0.35	0.79	0.5	0.4	0.66	0.33	0.51	0.51	0.71	0.21	0.2	0.61	0.52	-0.54	-0.12	-0.21	-0.11
Net Receivables	0.95	0.97	-0.16	0.09	0.26		0.6	0.96	0.18	0.29	-0.21	0.61	0.41	0.93	0.28	0.64	0.97	0.75	0.79	0.62	-0.4	0.86	0.72	0.85
Total Liab	0.78	0.68	0.54	-0.57	0.66	0.6		0.71	0.68	0.71	0.18	0.92	0.82	0.78	0.48	0.86	0.63	0.76	0.89	0.68	-0.41	0.44	0.28	0.18
Total Current Assets	0.97	0.97	-0.09	-0.06	0.35	0.96	0.71		0.27	0.45	-0.11	0.72	0.58	0.96	0.41	0.69	0.96	0.82	0.84	0.62	-0.44	0.8	0.7	0.78
Intangible Assets	0.41	0.31	0.55	-0.76	0.79	0.18	0.68	0.27		0.58	0.22	0.65	0.55	0.48	0.42	0.78	0.2	0.29	0.58	0.57	-0.51	-0.1	-0.11	-0.14
Short Term Investments	0.46	0.37	0.65	-0.65	0.5	0.29	0.71	0.45	0.58		-0.08	0.58	0.66	0.49	0.24	0.61	0.33	0.43	0.59	0.31	-0.51	0.08	0.09	-0.01
Short Term Debt	-0.14	-0.22	0.04	-0.35	0.4	-0.21	0.18	-0.11	0.22	-0.08		0.18	0.04	-0.13	0.41	-0.05	-0.28	-0.07	-0.09	0.03	0.28	-0.35	-0.42	-0.32
Common Stock	0.77	0.69	0.34	-0.55	0.66	0.61	0.92	0.72	0.65	0.58	0.18		0.79	0.78	0.37	0.81	0.61	0.72	0.86	0.66	-0.44	0.42	0.35	0.2
Long Term Debt	0.64	0.56	0.42	-0.44	0.33	0.41	0.82	0.58	0.55	0.66	0.04	0.79		0.62	0.41	0.63	0.53	0.74	0.69	0.37	-0.26	0.36	0.36	0.12
Property Plant Equipment	0.98	0.97	0.04	-0.22	0.51	0.93	0.78	0.96	0.48	0.49	-0.13	0.78	0.62		0.44	0.82	0.93	0.78	0.91	0.7	-0.56	0.71	0.6	0.7
Current Deferred Revenue	0.42	0.37	0.0	-0.39	0.51	0.28	0.48	0.41	0.42	0.24	0.41	0.37	0.41	0.44		0.52	0.36	0.48	0.53	0.51	-0.38	0.13	0.08	0.12
Good Will	0.79	0.73	0.39	-0.5	0.71	0.64	0.86	0.69	0.78	0.61	-0.05	0.81	0.63	0.82	0.52		0.67	0.72	0.94	0.8	-0.59	0.46	0.4	0.26
Net Tangible Assets	0.97	0.99	-0.12	0.1	0.21	0.97	0.63	0.96	0.2	0.33	-0.28	0.61	0.53	0.93	0.36	0.67		0.82	0.82	0.65	-0.41	0.89	0.78	0.84
Long Term Debt Total	0.84	0.82	0.06	-0.03	0.2	0.75	0.76	0.82	0.29	0.43	-0.07	0.72	0.74	0.78	0.48	0.72	0.82		0.85	0.62	-0.25	0.8	0.78	0.48
Capital Surpluse	0.9	0.85	0.26	-0.39	0.61	0.79	0.89	0.84	0.58	0.59	-0.09	0.86	0.69	0.91	0.53	0.94	0.82	0.85		0.77	-0.56	0.63	0.54	0.41
Long Term Investments	0.73	0.7	0.19	-0.26	0.52	0.62	0.68	0.62	0.57	0.31	0.03	0.66	0.37	0.7	0.51	0.8	0.65	0.62	0.77		-0.58	0.53	0.34	0.4
Short Long Term Debt	-0.48	-0.46	-0.16	0.53	-0.54	-0.4	-0.41	-0.44	-0.51	-0.51	0.28	-0.44	-0.26	-0.56	-0.38	-0.59	-0.41	-0.25	-0.56	-0.58		-0.1	-0.08	-0.23
Net Invested Capital	0.8	0.85	-0.21	0.44	-0.12	0.86	0.44	0.8	-0.1	0.08	-0.35	0.42	0.36	0.71	0.13	0.46	0.89	0.8	0.63	0.53	-0.1		0.88	0.8
Net Working Capital	0.67	0.73	-0.37	0.47	-0.21	0.72	0.28	0.7	-0.11	0.09	-0.42	0.35	0.36	0.6	0.08	0.4	0.78	0.78	0.54	0.34	-0.08	0.88		0.69
Capital Stock	0.74	0.82	-0.47	0.45	-0.11	0.85	0.18	0.78	-0.14	-0.01	-0.32	0.2	0.12	0.7	0.12	0.26	0.84	0.48	0.41	0.4	-0.23	0.8	0.69

Click cells to compare fundamentals

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as Operating Income, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	484.2 M	508.4 M
Non Operating Income Net Other	12.1 M	7.1 M

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

6.449

Earnings Share

2.21

Revenue Per Share

15.018

Quarterly Revenue Growth

0.156

Return On Assets

0.0515

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Operating Income from 2010 to 2025

Latest Biomarin Pharmaceutical's Operating Income Growth Pattern

Biomarin Operating Income Regression Statistics

Biomarin Operating Income History

Other Fundumenentals of Biomarin Pharmaceutical

Biomarin Pharmaceutical Operating Income component correlations

About Biomarin Pharmaceutical Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY